Millipore Sigma Vibrant Logo

HAIAB-10K MILLIPLEX MAP Human Autoimmune Autoantibody Panel

The Human Autoimmune Autoantibody panel is a bead-based multiplex assay based on the Luminex xMAP technology which enables the simultaneous analysis of autoimmune autoantibodies in human serum and plasma samples.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
Key Applications: Multiplexing Detection Methods: Luminex xMAP Research Category: Immune Response Research Sub-Category: Autoimmune disease, Inflammation, Immune Response, Immune Disorders
View Products on Sigmaaldrich.com
HAIAB-10K
Diseñe y calcule el precio de su kit

Descripción

Replacement Information

Tabla espec. clave

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
β2-Glycoprotein C1q CENP-B (Centromere Protein B) CENP-A (Centromere Protein A) Jo-1 Ku Mi-2 Myeloperoxidase (MPO) PCNA (Proliferating Cell Nuclear Antigen A) PL-12 (Alanyl-tRNA synthetase) PM/Scl 100 Proteinase 3 RNP (Ribonucleoprotein) RNP/Smith (RNP/Sm) Ribosomal P Scl-70 Sm SSB/La (Sjögren’s Syndrome-related antigen B/La) SSA/Ro60 (Sjögren’s Syndrome-related antigen A/Ro60 kDa) SSA/Ro52 (Sjögren’s Syndrome-related antigen A/Ro52 kDa) HMplexLuminex xMAP
Description
Catalogue NumberHAIAB-10K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX MAP Human Autoimmune Autoantibody Panel
OverviewThe MILLIPLEX® MAP Human Autoimmune Autoantibody Magnetic Bead Panel is a 20-plex kit to be used for the simultaneous detection and profiling of any or all of the following analytes in serum and plasma samples: Anti-C1q, Anti-Centromere Protein A (CENP-A), Anti-Centromere Protein B (CENP-B), Anti-β 2-Glycoprotein, Anti-Jo-1, Anti-Ku, Anti-Mi-2, Anti-Myeloperoxidase, Anti-Proliferating cell nuclear antigen A (PCNA), Anti-Alanyl-tRNA synthetase (PL-12), Anti-PM/Scl-100, Anti-Proteinase 3, Anti-Ribosomal P, Anti-Ribonucleoprotein (RNP), Anti-RNP/Smith (RNP/Sm), Anti-Scl-70, Anti-Sm, Anti-Sjögren’s Syndrome-related antigen B/La (SSB/La), Anti-Anti-Sjögren’s Syndrome-related antigen A/Ro52 kDa (SSA/Ro52), Anti-Sjögren’s Syndrome-related antigen A/Ro60 kDa (SSA/Ro60). For this particular panel, 4 assay control beads are also included as part of the base kit format.
Background InformationAutoantibody formation is principal to the pathogenesis of a variety of autoimmune diseases. Dysregulated apoptosis and the subsequent defective clearance of cellular debris leads to the exposure of autoantigens and the generation of autoantibodies. The presence of autoantibodies may indicate disease activity, prognosis, and clinical associations related to a variety of autoimmune diseases. These autoimmune diseases include, but are not limited to, Sjögren’s Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Systemic Sclerosis, Calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia (CREST syndrome), Polymyositis/Dermatomyositis, Vasculitis, Anti-Phospholipid Syndrome, and various overlap syndromes of these diseases.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Intra-assay: <10%
  • Inter-assay: <20%
Panel TypeMAGNETIC Immune Response
Applications
ApplicationThe Human Autoimmune Autoantibody panel is a bead-based multiplex assay based on the Luminex xMAP technology which enables the simultaneous analysis of autoimmune autoantibodies in human serum and plasma samples.
Key Applications
  • Multiplexing
Application Notes• This is assay yields results in Median Fluorescence Intensity (MFI).
• Four assay control beads are included in the base kit.
• This is an overnight assay.
• This assay requires 25 µL of 1:100 diluted plasma or serum.
Biological Information
Species Reactivity
  • Human
Analytes Available
  • β2-Glycoprotein
  • C1q
  • CENP-B (Centromere Protein B)
  • CENP-A (Centromere Protein A)
  • Jo-1
  • Ku
  • Mi-2
  • Myeloperoxidase (MPO)
  • PCNA (Proliferating Cell Nuclear Antigen A)
  • PL-12 (Alanyl-tRNA synthetase)
  • PM/Scl 100
  • Proteinase 3
  • RNP (Ribonucleoprotein)
  • RNP/Smith (RNP/Sm)
  • Ribosomal P
  • Scl-70
  • Sm
  • SSB/La (Sjögren’s Syndrome-related antigen B/La)
  • SSA/Ro60 (Sjögren’s Syndrome-related antigen A/Ro60 kDa)
  • SSA/Ro52 (Sjögren’s Syndrome-related antigen A/Ro52 kDa)
Assay PanelEverything you need in a single kit.
Cross ReactivitySamples were incubated with no antigen, irrelevant antigen, or specific antigen. Incubation with a partcular antigen led to selective abrogation of the reactivity, while reactivity was unaffected by the irrelevant antigen.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Material Package96 well plate
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
HAIAB-10K 04054839517433

Documentation

MILLIPLEX MAP Human Autoimmune Autoantibody Panel Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Referencias bibliográficas

Visión general referenciasPub Med ID
Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease.
Kwon J, Surenkhuu B, Raju I, et al.
Ocul Surf.  18(1): 80-97.  2020

31606460 31606460
RF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE.
Li D, Matta B, Song S, et al.
JCI Insight.  2020

31877114 31877114